Grace Therapeutics Inc.

NASDAQ: GRCE · Real-Time Price · USD
3.21
0.13 (4.22%)
At close: Aug 15, 2025, 12:15 PM

Grace Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
Net Income
-9.57M -12.85M -42.43M -9.82M
Depreciation & Amortization
7K 11K 124K n/a
Stock-Based Compensation
730K 913K 1.81M 1.34M
Other Working Capital
-254K -1.36M 483K -2.77M
Other Non-Cash Items
-3.22M 2.71M 33.94M -5.32M
Deferred Income Tax
-3.2M -1.83M -9.54M -648K
Change in Working Capital
342K -1.28M 181K -2.79M
Operating Cash Flow
-14.9M -12.33M -15.91M -17.23M
Capital Expenditures
n/a -22K -17K n/a
Cash Acquisitions
n/a 111K n/a n/a
Purchase of Investments
-15K -6.55M -5.01M -34.93M
Sales Maturities Of Investments
15K 6.57M 18.18M 31.41M
Other Investing Acitivies
n/a n/a n/a n/a
Investing Cash Flow
n/a 104K 13.15M -3.52M
Debt Repayment
n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a 21K n/a n/a
Financial Cash Flow
14.03M 7.36M 304K n/a
Net Cash Flow
-872K -4.87M -2.46M -20.6M
Free Cash Flow
-14.9M -12.36M -15.93M -17.23M